Close this search box.

Insights from Bob Nelsen and developments in TL1A inhibitors, rare diseases: BioCentury’s latest podcast

Plus: The latest on anti-China policies in Congress

By Jeff Cranmer, Executive Editor

February 27, 2024 1:49 AM UTC

Arch Venture Partners’ Bob Nelsen is excited about AI’s potential in biotech and convinced the U.S. healthcare system could do a far better job delivering on the promise of the biopharma industry’s innovations. On the latest BioCentury This Week podcast, BioCentury’s editors discuss takeaways from Nelsen’s appearance on The BioCentury Show, including how the longtime investor in China’s life sciences sector has adopted a more cautious stance on the country given increasing geopolitical tensions.

BioCentury’s editors also discuss whether TL1A inhibitors are poised to bring precision medicine to large inflammatory and autoimmune indications, and why participants in a Feb. 21 Reagan-Udall Foundation workshop hope the meeting could help establish precedents that will revitalize the development of effective treatments for extremely rare diseases.

For information on how to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact BioCentury at